Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes.

Zhu J, Powis de Tenbossche CG, Cané S, Colau D, van Baren N, Lurquin C, Schmitt-Verhulst AM, Liljeström P, Uyttenhove C, Van den Eynde BJ.

Nat Commun. 2017 Nov 10;8(1):1404. doi: 10.1038/s41467-017-00784-1.

2.

Distinct patterns of cytolytic T-cell activation by different tumour cells revealed by Ca2+ signalling and granule mobilization.

Frick M, Mouchacca P, Verdeil G, Hamon Y, Billaudeau C, Buferne M, Fallet M, Auphan-Anezin N, Schmitt-Verhulst AM, Boyer C.

Immunology. 2017 Feb;150(2):199-212. doi: 10.1111/imm.12679. Epub 2016 Nov 2.

3.

Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion.

Giordano M, Henin C, Maurizio J, Imbratta C, Bourdely P, Buferne M, Baitsch L, Vanhille L, Sieweke MH, Speiser DE, Auphan-Anezin N, Schmitt-Verhulst AM, Verdeil G.

EMBO J. 2015 Aug 4;34(15):2042-58. doi: 10.15252/embj.201490786. Epub 2015 Jul 2.

4.

IFNγ producing CD8+ T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas.

Buferne M, Chasson L, Grange M, Mas A, Arnoux F, Bertuzzi M, Naquet P, Leserman L, Schmitt-Verhulst AM, Auphan-Anezin N.

Oncoimmunology. 2015 Mar 6;4(2):e974959. eCollection 2015 Feb.

5.

Unleashing antitumor T-cell activation without ensuing autoimmunity: the case for A20-deletion in adoptive CD8+ T-cell therapy.

Verdeil G, Schmitt-Verhulst AM.

Oncoimmunology. 2014 Dec 15;3(10):e958951. eCollection 2014 Oct.

6.

Control of CD8 T cell proliferation and terminal differentiation by active STAT5 and CDKN2A/CDKN2B.

Grange M, Giordano M, Mas A, Roncagalli R, Firaguay G, Nunes JA, Ghysdael J, Schmitt-Verhulst AM, Auphan-Anezin N.

Immunology. 2015 Aug;145(4):543-57. doi: 10.1111/imm.12471. Epub 2015 Jun 15.

7.

Silence STAT3 in the procancer niche… and activate CD8+ T cells to kill premetastatic myeloid intruders.

Auphan-Anezin N, Schmitt-Verhulst AM.

Eur J Immunol. 2015 Jan;45(1):44-8. doi: 10.1002/eji.201445300.

8.

Visualization of granzyme B-expressing CD8 T cells during primary and secondary immune responses to Listeria monocytogenes.

Mouchacca P, Chasson L, Frick M, Foray C, Schmitt-Verhulst AM, Boyer C.

Immunology. 2015 May;145(1):24-33. doi: 10.1111/imm.12420.

9.

The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells.

Giordano M, Roncagalli R, Bourdely P, Chasson L, Buferne M, Yamasaki S, Beyaert R, van Loo G, Auphan-Anezin N, Schmitt-Verhulst AM, Verdeil G.

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11115-20. doi: 10.1073/pnas.1406259111. Epub 2014 Jul 14.

10.

Active STAT5 regulates T-bet and eomesodermin expression in CD8 T cells and imprints a T-bet-dependent Tc1 program with repressed IL-6/TGF-β1 signaling.

Grange M, Verdeil G, Arnoux F, Griffon A, Spicuglia S, Maurizio J, Buferne M, Schmitt-Verhulst AM, Auphan-Anezin N.

J Immunol. 2013 Oct 1;191(7):3712-24. doi: 10.4049/jimmunol.1300319. Epub 2013 Sep 4.

11.

Visualization of cytolytic T cell differentiation and granule exocytosis with T cells from mice expressing active fluorescent granzyme B.

Mouchacca P, Schmitt-Verhulst AM, Boyer C.

PLoS One. 2013 Jun 28;8(6):e67239. doi: 10.1371/journal.pone.0067239. Print 2013.

12.

Immunosuppression in inflammatory melanoma: can it be resisted by adoptively transferred T cells?

Auphan-Anezin N, Verdeil G, Grange M, Soudja SM, Wehbe M, Buferne M, Mas A, Schmitt-Verhulst AM.

Pigment Cell Melanoma Res. 2013 Mar;26(2):167-75. doi: 10.1111/pcmr.12056. Epub 2012 Dec 27.

PMID:
23217139
13.

Epithelial-mesenchymal-transition-like and TGFβ pathways associated with autochthonous inflammatory melanoma development in mice.

Wehbe M, Soudja SM, Mas A, Chasson L, Guinamard R, de Tenbossche CP, Verdeil G, Van den Eynde B, Schmitt-Verhulst AM.

PLoS One. 2012;7(11):e49419. doi: 10.1371/journal.pone.0049419. Epub 2012 Nov 16.

14.

Minimal tolerance to a tumor antigen encoded by a cancer-germline gene.

Huijbers IJ, Soudja SM, Uyttenhove C, Buferne M, Inderberg-Suso EM, Colau D, Pilotte L, Powis de Tenbossche CG, Chomez P, Brasseur F, Schmitt-Verhulst AM, Van den Eynde BJ.

J Immunol. 2012 Jan 1;188(1):111-21. doi: 10.4049/jimmunol.1002612. Epub 2011 Dec 2.

15.

Granzyme B-tdTomato, a new probe to visualize cytolytic effector cell activation.

Mouchacca P, Guyot V, Grégoire C, Schmitt-Verhulst AM, Boyer C.

Eur J Immunol. 2012 Jan;42(1):264-6. doi: 10.1002/eji.201141671. Epub 2011 Dec 12. No abstract available.

16.

Activated STAT5 promotes long-lived cytotoxic CD8+ T cells that induce regression of autochthonous melanoma.

Grange M, Buferne M, Verdeil G, Leserman L, Schmitt-Verhulst AM, Auphan-Anezin N.

Cancer Res. 2012 Jan 1;72(1):76-87. doi: 10.1158/0008-5472.CAN-11-2187. Epub 2011 Nov 7.

17.

Disrupted lymph node and splenic stroma in mice with induced inflammatory melanomas is associated with impaired recruitment of T and dendritic cells.

Soudja SM, Henri S, Mello M, Chasson L, Mas A, Wehbe M, Auphan-Anezin N, Leserman L, Van den Eynde B, Schmitt-Verhulst AM.

PLoS One. 2011;6(7):e22639. doi: 10.1371/journal.pone.0022639. Epub 2011 Jul 21.

18.

Selection of T-cell receptors with a recurrent CDR3β peptide-contact motif within the repertoire of alloreactive CD8(+) T cells.

Scifo C, Mekaelian L, Munyazesa E, Schmitt-Verhulst AM, Guimezanes A.

Eur J Immunol. 2011 Aug;41(8):2414-23. doi: 10.1002/eji.201141494. Epub 2011 Jun 24.

19.

Tumor-initiated inflammation overrides protective adaptive immunity in an induced melanoma model in mice.

Soudja SM, Wehbe M, Mas A, Chasson L, de Tenbossche CP, Huijbers I, Van den Eynde B, Schmitt-Verhulst AM.

Cancer Res. 2010 May 1;70(9):3515-25. doi: 10.1158/0008-5472.CAN-09-4354. Epub 2010 Apr 20.

20.

Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity.

Shanker A, Buferne M, Schmitt-Verhulst AM.

Immunology. 2010 Jan;129(1):41-54. doi: 10.1111/j.1365-2567.2009.03150.x.

21.

CD8 T cell help for innate antitumor immunity.

Shanker A, Verdeil G, Buferne M, Inderberg-Suso EM, Puthier D, Joly F, Nguyen C, Leserman L, Auphan-Anezin N, Schmitt-Verhulst AM.

J Immunol. 2007 Nov 15;179(10):6651-62.

22.

How much can a T-cell antigen receptor adapt to structurally distinct antigenic peptides?

Mazza C, Auphan-Anezin N, Gregoire C, Guimezanes A, Kellenberger C, Roussel A, Kearney A, van der Merwe PA, Schmitt-Verhulst AM, Malissen B.

EMBO J. 2007 Apr 4;26(7):1972-83. Epub 2007 Mar 15.

23.

Temporal cross-talk between TCR and STAT signals for CD8 T cell effector differentiation.

Verdeil G, Chaix J, Schmitt-Verhulst AM, Auphan-Anezin N.

Eur J Immunol. 2006 Dec;36(12):3090-100. Review.

24.

Distinct orientation of the alloreactive monoclonal CD8 T cell activation program by three different peptide/MHC complexes.

Auphan-Anezin N, Mazza C, Guimezanes A, Barrett-Wilt GA, Montero-Julian F, Roussel A, Hunt DF, Malissen B, Schmitt-Verhulst AM.

Eur J Immunol. 2006 Jul;36(7):1856-66.

25.

STAT5-mediated signals sustain a TCR-initiated gene expression program toward differentiation of CD8 T cell effectors.

Verdeil G, Puthier D, Nguyen C, Schmitt-Verhulst AM, Auphan-Anezin N.

J Immunol. 2006 Apr 15;176(8):4834-42.

26.

An inducible mouse model of melanoma expressing a defined tumor antigen.

Huijbers IJ, Krimpenfort P, Chomez P, van der Valk MA, Song JY, Inderberg-Suso EM, Schmitt-Verhulst AM, Berns A, Van den Eynde BJ.

Cancer Res. 2006 Mar 15;66(6):3278-86.

27.

Selective defect in antigen-induced TCR internalization at the immune synapse of CD8 T cells bearing the ZAP-70(Y292F) mutation.

Davanture S, Leignadier J, Milani P, Soubeyran P, Malissen B, Malissen M, Schmitt-Verhulst AM, Boyer C.

J Immunol. 2005 Sep 1;175(5):3140-9.

28.

RelA regulates the survival of activated effector CD8 T cells.

Mondor I, Schmitt-Verhulst AM, Guerder S.

Cell Death Differ. 2005 Nov;12(11):1398-406.

29.

Thymocyte-intrinsic genetic factors influence CD8 T cell lineage commitment and affect selection of a tumor-reactive TCR.

Shanker A, Auphan-Anezin N, Chomez P, Giraudo L, Van den Eynde B, Schmitt-Verhulst AM.

J Immunol. 2004 Apr 15;172(8):5069-77.

30.

Differential implication of protein kinase C isoforms in cytotoxic T lymphocyte degranulation and TCR-induced Fas ligand expression.

Pardo J, Buferne M, Martínez-Lorenzo MJ, Naval J, Schmitt-Verhulst AM, Boyer C, Anel A.

Int Immunol. 2003 Dec;15(12):1441-50.

PMID:
14645153
31.

Structural and kinetic basis for low affinity cross-reactivity in T cell allorecognition.

Guimezanes A, Montero-Julian F, Schmitt-Verhulst AM.

Eur J Immunol. 2003 Nov;33(11):3060-9.

32.
33.

Gene profiling approach to establish the molecular bases for partial versus full activation of naïve CD8 T lymphocytes.

Verdeil G, Puthier D, Nguyen C, Schmitt-Verhulst AM, Auphan-Anezin N.

Ann N Y Acad Sci. 2002 Dec;975:68-76.

PMID:
12538155
34.

A novel reporter strain to follow Cre-mediated recombination in T and NK cells.

Wurtz O, Pophillat M, Schmitt-Verhulst AM, Guerder S.

Genesis. 2002 Apr;32(4):287-92.

PMID:
11948916
35.

A T cell receptor CDR3beta loop undergoes conformational changes of unprecedented magnitude upon binding to a peptide/MHC class I complex.

Reiser JB, Grégoire C, Darnault C, Mosser T, Guimezanes A, Schmitt-Verhulst AM, Fontecilla-Camps JC, Mazza G, Malissen B, Housset D.

Immunity. 2002 Mar;16(3):345-54.

36.
37.

Crystal structure of a T cell receptor bound to an allogeneic MHC molecule.

Reiser JB, Darnault C, Guimezanes A, Grégoire C, Mosser T, Schmitt-Verhulst AM, Fontecilla-Camps JC, Malissen B, Housset D, Mazza G.

Nat Immunol. 2000 Oct;1(4):291-7. Erratum in: Nat Immunol 2000 Nov;1(5):447.

PMID:
11017099
38.

Regulation of activator protein-1 and NF-kappa B in CD8+ T cells exposed to peripheral self-antigens.

Guerder S, Rincòn M, Schmitt-Verhulst AM.

J Immunol. 2001 Apr 1;166(7):4399-407.

39.

Identification of endogenous peptides recognized by in vivo or in vitro generated alloreactive cytotoxic T lymphocytes: distinct characteristics correlated with CD8 dependence.

Guimezanes A, Barrett-Wilt GA, Gulden-Thompson P, Shabanowitz J, Engelhard VH, Hunt DF, Schmitt-Verhulst AM.

Eur J Immunol. 2001 Feb;31(2):421-32. Erratum in: Eur J Immunol 2001 Apr;31(4):1298. Engelhardt VH [corrected to Engelhard VH].

40.

The lack of NF-kappa B transactivation and PKC epsilon expression in CD4(+)CD8(+) thymocytes correlates with negative selection.

Simon AK, Auphan N, Pophillat M, Boyer C, Ghosh S, Rincón M, Flavell RA, Schmitt-Verhulst AM.

Cell Death Differ. 2000 Dec;7(12):1253-62.

41.
42.

Antigen-induced TCR-CD3 down-modulation does not require CD3delta or CD3gamma cytoplasmic domains, necessary in response to anti-CD3 antibody.

Legendre V, Guimezanes A, Buferne M, Barad M, Schmitt-Verhulst AM, Boyer C.

Int Immunol. 1999 Nov;11(11):1731-8.

PMID:
10545476
43.

Selection of phenotypically distinct NK1.1+ T cells upon antigen expression in the thymus or in the liver.

Legendre V, Boyer C, Guerder S, Arnold B, Hämmerling G, Schmitt-Verhulst AM.

Eur J Immunol. 1999 Jul;29(7):2330-43.

44.

Consequences of intrathymic TCR engagement by partial agonist on selection events and peripheral T cell activation program.

Auphan N, Simon AK, Asnagli H, Phillips RJ, Rincon M, Ghosh S, Flavell RA, Schmitt-Verhulst AM.

J Immunol. 1998 May 15;160(10):4810-21.

45.

Interferon-regulatory factors during development of CD4 and CD8 thymocytes.

Simon AK, Desrois M, Schmitt-Verhulst AM.

Immunology. 1997 Jul;91(3):340-5.

46.

Class I- and class II-reactive TCRs coexpressed on CD4+ T cells both trigger CD4/CD8-shared and CD4-unique functions.

Asnagli H, Schmitt-Verhulst AM, Guimezanes A.

J Immunol. 1997 May 15;158(10):4533-42.

PMID:
9144464
47.

Role of CD3gamma and CD3delta cytoplasmic domains in cytolytic T lymphocyte functions and TCR/CD3 down-modulation.

Luton F, Buferne M, Legendre V, Chauvet E, Boyer C, Schmitt-Verhulst AM.

J Immunol. 1997 May 1;158(9):4162-70.

PMID:
9126976
48.

Tyrosine and serine protein kinase activities associated with ligand-induced internalized TCR/CD3 complexes.

Luton F, Legendre V, Gorvel JP, Schmitt-Verhulst AM, Boyer C.

J Immunol. 1997 Apr 1;158(7):3140-7.

PMID:
9120267
49.

Inhibition of CPP32-like proteases prevents granzyme B- and Fas-, but not granzyme A-based cytotoxicity exerted by CTL clones.

Anel A, Gamen S, Alava MA, Schmitt-Verhulst AM, Piñeiro A, Naval J.

J Immunol. 1997 Mar 1;158(5):1999-2006.

PMID:
9036942
50.

Influence on CD8 of TCR/CD3-generated signals in CTL clones and CTL precursor cells.

Anel A, Martínez-Lorenzo MJ, Schmitt-Verhulst AM, Boyer C.

J Immunol. 1997 Jan 1;158(1):19-28.

PMID:
8977171

Supplemental Content

Loading ...
Support Center